Seeking Alpha

Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.

PharmAthene (PIP) is poised to jump. Three recent developments have affected its stock price:

  • the flu product of its prospective merger partner (Theraclone Sciences) failed to reach its clinical trial's primary endpoint, after which the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) declined funding;
  • PharmAthene terminated its merger with Theraclone; and
  • the FDA placed a clinical hold on SparVax, PharmAthene's anthrax product.

There has also been a lack of news about the seven-year legal battle with SIGA Technologies (...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: